Myopharm strives to enhance & prolong lives in those with metabolic and inflammatory diseases
Myopharm Limited is a clinical-stage Australian-based biopharmaceutical company, developing targeted therapies for multiple chronic diseases.
In our portfolio we have pharmaceutical drug candidates & clinically validated consumer health products.
We were incredibly honoured that the American Diabetes Association(ADA) accepted our Preclinical Data Abstract & Poster as part of the ADA’s 86th Scientific Sessions program June 2026.
See our latest OMNI-D® Television Commercial
PORTFOLIO
Drug Candidates
Myopharm’s lead drug candidate TriGlytza®, reduces progressive pancreatic Beta cell loss through targeted action on multiple pro-inflammatory mediators within the PGE2 & RAS signalling pathways.
Consumer Health
Myopharm's clinically validated food for special medical purpose products are high-quality treatments that aid in the management of diabetes & chronic disease
OUR MISSION
Myopharm strives to enhance & prolong lives through the development of specialised assets that effectively treat multiple metabolic mediated inflammatory chronic diseases.
Our goal is to empower patients, healthcare providers & communities globally through our innovative suite of products that treat and manage chronic diseases.
INVESTOR CENTRE
Our Study Partners
